Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endoret PRGF for ocular surface regeneration in glaucoma
2025-520642-29-00Phase 2Authorised
- Sponsor
- Hospital de la Santa Creu i Sant Pau Research Institute
- Start
- Jan 2025
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PRGF-Endoret in Glaucoma and ocular surface disease (OSD), sponsored by Hospital de la Santa Creu i Sant Pau Research Institute. Primary endpoint: Tear osmolarity change from baseline to V2. Planned start Jan 2025; status: authorised.
02
Drugs
PRGF-Endoret
03
Conditions
Glaucomaocular surface disease (OSD)
Beyond the preview
Go deeper on 2025-520642-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520642-29-00.